Hmmzis wrote: » Very, very much would like to see the results of this vaccine in humans. We have to keep in mind that this is intended to be a single dose shot (it can be boosted, but we want as many doses available as possible), so the numbers most likely will not rival the prime-boost candidates. If you're looking for numbers, all we need from it are nAB titers in the 1:30 region and overall titers to go to 1:320 or above (in line with Mt Sinai convalescent plasma research). If that is paired with a good T cell response, then it should offer solid protection for the average individual. If we don't see that, it's still not a big loss as even 1:8 nAB titers have shown reasonable results, add some decent T cell responses and we might see something that prevents people from needing hospital treatment and dying.
Santy2015 wrote: » Even at the 1:8 would regulators/governments sign off on it and give the go ahead after phase 3? Even if we need boosters after a year like the flu vaccine.
We performed an integrated immune analysis on a cohort of 50 COVID-19 patients with various disease severity. A unique phenotype was observed in severe and critical patients, consisting of a highly impaired interferon (IFN) type I response and an exacerbated inflammatory response.
Azatadine wrote: » Not vaccine but treatment related.https://www.bbc.com/news/health-53467022
Hmmzis wrote: » Regulator approval is entirely dependent on phase 3 results. FDA have said that they'll approve anything with 50% or grater efficacy. While we can measure antibody levels and do neutralisation assays, we can't quite predict how that will work in a human when exposed to the real deal. We can make some comparisons and extrapolations from convalescent serum studies and compare similar animal studies, at the end it's still only an educated guess.
Gael23 wrote: » The FDA will do what Trump orders them to do. Who has to give approval for this to be used in Europe? Why are the UK ordering so many doses? https://www.rte.ie/news/business/2020/0720/1154313-britain-signs-deals-for-covid-19-vaccines/
ACitizenErased wrote: » Is Oxford data being released today?
High levels of neutralising antibody at baseline seen in a small number of participants probably indicates prior asymptomatic infection, as potential participants with recent COVID-19-like symptoms or with a history of positive PCR test for SARS-CoV-2 were excluded from the study. Individuals with high titres on the day of vaccination who received ChAdOx1 nCoV-19 were boosted by vaccination.
Hmmzis wrote: » And here is the ChAdOx1 phase 1/2 publication:https://marlin-prod.literatumonline.com/pb-assets/Lancet/pdfs/S0140673620316044.pdf
Gael23 wrote: » What volume can AstraZeneca produce quickly?
Icantthinkof1 wrote: » Great news! Out of interest; what will phase 3 consist of? Excuse my ignorance on this but will phase 3 be the same study as phase 2 but will they be testing the vaccine on more people than they did in phase2 or will they test it on more vulnerable people like the elderly; those with underlying conditions?
Stark wrote: » 2 billion apparently https://medicalxpress.com/news/2020-06-astrazeneca-track-virus-vaccine-september.html . They've had a head start since earlier in the year.
marno21 wrote: » Have they started manufacturing en masse already? Given the results to date, it would be fantastic if manufacturing began now. The financial risk of it not working out is substantially less than the benefits of being able to have a mass rollout in the event the Phase III trials are successful.
Danzy wrote: » Seems the Chinese have given the military a vaccine already. Guinea pigs.
seanb85 wrote: » Given the way they are treating the Uighur Muslims, I would be surprised if they're not secretly carrying out challenge trials.
Gael23 wrote: » When they say the vaccine should be available in limited quantities towards the end of the year, do we know how limited?
